[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100482013":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":30,"responsibleParty":47,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":10,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":10,"overallStatus":68,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"HPT patients",null,"Patients with primary hyperparathyroidism at diagnosis (HPT) treated with parathyroidectomy (HPT-PTX)",[13],"Diagnostic Test: Biomarker assays",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Biomarker assays","Circulating bone biomarkers assays",[9],[21],{"name":22,"affiliation":23,"role":24},"Sabrina Corbetta, PhD, MD","IRCCS Istituto Ortopedico Galeazzi","PRINCIPAL_INVESTIGATOR",[26],{"name":22,"role":27,"phone":28,"phoneExt":10,"email":29},"CONTACT","+39 02 83506781","sabrina.corbetta@unimi.it",[31],{"facility":23,"status":10,"city":32,"state":10,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Milan","20157","Italy","IT",{"type":37,"coordinates":38},"Point",[39,40],9.18951,45.46427,{"lat":40,"lon":39},[43,44],{"name":22,"role":27,"phone":10,"phoneExt":10,"email":29},{"name":45,"role":27,"phone":10,"phoneExt":10,"email":46},"Sara Zacchetti","sara.zacchetti@grupposandonato.it",{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100482013","the-bone-parathyroid-crosstalk-in-primary-hyperparathyroidism-100482013",false,"NCT05556499","The Bone-parathyroid Crosstalk in Primary Hyperparathyroidism","Interactions Between Bone and Parathyroid Tumors in Patiens With Primary Hyperparathyroidism (The PARABONE Study)","PARABONE","Inclusion Criteria:\n\nInclusion criteria for the HPT patient group:\n\n* diagnosis of primary hyperparathyroidism according to the most recent guidelines \\[Marcocci et al. 2015\\];\n* adult patients (age ≥ 18 years);\n* signature of the informed consent.\n\nInclusion criteria for the HPT-PTX patient group:\n\n* diagnosis of primary hyperparathyroidism with indication of surgical removal of the parathyroid tumor according to the most recent guidelines \\[Marcocci et al. 2015\\];\n* adult patients (age ≥18 years);\n* signature of the informed consent.\n\nExclusion Criteria:\n\n* Criteria for exclusion from the study are:\n* age \\\u003C18 years\n* diagnosis of hyperparathyroidism secondary to chronic renal failure or to vitamin D or calcium deficiency;\n* pregnancy or breastfeeding (self-declaration)\n* lack of informed consent","ALL","18 Years",{"count":60,"type":61},100,"ESTIMATED","OBSERVATIONAL","The PARABONE study aims to investigate the interaction between bone and parathyroid glands in patients with primary hyperparathyroidism (HPT). The study consists of a clinical part aimed at evaluating a series of circulating molecules of bone derivation (osteocalcin, molecules of the WNT pathway, RANKL, osteoprotegerin, Scelrostin, FGF23) in patients with HPT. In particular, the study has as its primary objective to identify the correlation between circulating levels of PTH and levels of GlaOC and GluOC in patients with HPT.",[65,66,67],"Hyperparathyroidism, Primary","Osteoporosis","Parathyroid Neoplasms","NOT_YET_RECRUITING","2022-09-28",{"date":71,"type":72},"2022-09-30","ACTUAL",{"date":74,"type":61},"2022-10",{"date":76,"type":61},"2026-06-24",{"name":5,"class":6},1]